Is intensive drug therapy appropriate for older patients?

Lancet

Volumn 353, Issue 9157, 1999, Pages 940-941

  Gollub, S B ^a  

^a UNIVERSITY OF KANSAS SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; FIBRINOLYTIC AGENT; STREPTOKINASE; TISSUE PLASMINOGEN ACTIVATOR;

AGED; BLEEDING; DRUG EFFICACY; DRUG USE; GERIATRIC CARE; HEART INFARCTION; HUMAN; NOTE; PRIORITY JOURNAL; STROKE;

EID: 0033586468     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(99)90024-7     Document Type: Note

References (6)

1. Soumerai SB McLaughlin TJ Spiegelman D Hertzmark E Thibault G Goldman L Adverse outcomes of underuse of β-blockers in elderly survivors of myocardial infarction JAMA 277 1997 115 121
2. McLaughlin TJ Soumerai SB Willison DJ Adherence to national guidelines for drug treatment of suspected acute myocardial infarction Arch Intern Med 156 1996 799 805
3. White HD Barbash GI Califf RM Age and outcome with contemporary thrombolytic therapy Circulation 94 1996 1826 1833
4. Gurwitz JH Col NF Avorn J The exclusion of the elderly and women from clinical trials in acute myocardial infarction JAMA 268 1992 1417 1422
5. Fibrinolytic Therapy Trialists' (FTT) Collaborative Group Indications for fibrinolytic therapy in suspected acute myocardial infarction:collaborative overview of early mortality and major morbidity results from all randomised trials of more than 1000 patients Lancet 343 1994 311 322
6. Krumholz HM Pasternak RC Weinstein MC Cost-effectiveness of thrombolytic therapy with streptokinase in elderly patients with suspected acute myocardial infarction N Engl J Med 327 1992 7 13